时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
With the rising global prevalence of inflammatory bowel disease (IBD) and improved patient longevity, the burden of colitis-associated colorectal cancer (CAC) is increasing. Patients with IBD have a higher risk of developing colorectal cancer (CRC) compared with the general population and are typically diagnosed at a younger age than thos…
对本项目的价值
参考价值：属「微生物组及其代谢物干预」方向；微生物组及其代谢物干预栏目可用作本项目文献库与综述素材。 ｜ 价值分 1.8/5（★★☆☆☆）
全文不可及原因
无 PMCID 且 Europe PMC / OpenAlex / Unpaywall 未提供可下载 OA 全文
原文题录
- 中文题名：细菌与药物：IBD 治疗、炎症与肠道菌群的互作及其对结肠致癌的启示
- 英文标题：Bugs and drugs: The interplay between IBD therapeutics, inflammation and the gut microbiome - implications for colonic carcinogenesis.
- 期刊与标识：Best practice & research. Clinical gastroenterology · PMID 42971662 · DOI 10.1016/j.bpg.2026.102139